Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis

Abstract Background Uveitic macular edema is a complication of acute or chronic uveitis. Current treatment regiments frequently have numerous side effects, often requiring supplemental treatment. This study investigates the efficacy of dexamethasone (DEX) intravitreal implants as monotherapy for tre...

Full description

Bibliographic Details
Main Authors: Rishi B. Gupta, Julius Ilin, Chloe C. Gottlieb
Format: Article
Language:English
Published: SpringerOpen 2023-09-01
Series:Journal of Ophthalmic Inflammation and Infection
Subjects:
Online Access:https://doi.org/10.1186/s12348-023-00360-3
_version_ 1797451804344057856
author Rishi B. Gupta
Julius Ilin
Chloe C. Gottlieb
author_facet Rishi B. Gupta
Julius Ilin
Chloe C. Gottlieb
author_sort Rishi B. Gupta
collection DOAJ
description Abstract Background Uveitic macular edema is a complication of acute or chronic uveitis. Current treatment regiments frequently have numerous side effects, often requiring supplemental treatment. This study investigates the efficacy of dexamethasone (DEX) intravitreal implants as monotherapy for treatment of macular edema in non-infectious intermediate, posterior or panuveitis. Methods and results Retrospective chart review of thirty patients with intermediate, posterior and panuveitis treated with DEX. Outcomes measured were central retinal thickness (CRT) and best corrected visual acuity (BCVA). Baseline measurements of CRT and BCVA were measured within 1 month prior to intravitreal DEX implant and follow up measurements were collected until 1 year post implant. 48 implants on 39 eyes of 30 patients were included in this study; 64.1% of patients had an improvement in BCVA and 65.4% had a reduction in CRT. BCVA improved from 0.285 logMAR (SD: 0.312) at baseline to 0.175 logMAR (SD: 0.194) at 1 month and was sustained thereafter. Preliminary CRT data showed a decrease from 392 $$\mu m$$ μ m (SD: $$161\mu m$$ 161 μ m ) at baseline to 303 $$\mu m$$ μ m (SD: $$80\mu m)$$ 80 μ m ) at 1 month and 313 $$\mu m$$ μ m (SD: $$44\mu m)$$ 44 μ m ) at 12 months. Conclusions The DEX implant as monotherapy for macular edema in non-infectious uveitis was associated with a reduction in CRT and improvement in BCVA. The DEX implant, used as a monotherapy in eyes with intermediate, posterior and panuveitis, has the potential to treat uveitis without oral corticosteroid or other immunomodulatory therapy.
first_indexed 2024-03-09T14:58:42Z
format Article
id doaj.art-136f12828389434a94328e80d60ccbde
institution Directory Open Access Journal
issn 1869-5760
language English
last_indexed 2024-03-09T14:58:42Z
publishDate 2023-09-01
publisher SpringerOpen
record_format Article
series Journal of Ophthalmic Inflammation and Infection
spelling doaj.art-136f12828389434a94328e80d60ccbde2023-11-26T13:59:21ZengSpringerOpenJournal of Ophthalmic Inflammation and Infection1869-57602023-09-011311710.1186/s12348-023-00360-3Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysisRishi B. Gupta0Julius Ilin1Chloe C. Gottlieb2Faculty of Medicine, University of OttawaFaculty of Medicine, University of OttawaFaculty of Medicine, University of OttawaAbstract Background Uveitic macular edema is a complication of acute or chronic uveitis. Current treatment regiments frequently have numerous side effects, often requiring supplemental treatment. This study investigates the efficacy of dexamethasone (DEX) intravitreal implants as monotherapy for treatment of macular edema in non-infectious intermediate, posterior or panuveitis. Methods and results Retrospective chart review of thirty patients with intermediate, posterior and panuveitis treated with DEX. Outcomes measured were central retinal thickness (CRT) and best corrected visual acuity (BCVA). Baseline measurements of CRT and BCVA were measured within 1 month prior to intravitreal DEX implant and follow up measurements were collected until 1 year post implant. 48 implants on 39 eyes of 30 patients were included in this study; 64.1% of patients had an improvement in BCVA and 65.4% had a reduction in CRT. BCVA improved from 0.285 logMAR (SD: 0.312) at baseline to 0.175 logMAR (SD: 0.194) at 1 month and was sustained thereafter. Preliminary CRT data showed a decrease from 392 $$\mu m$$ μ m (SD: $$161\mu m$$ 161 μ m ) at baseline to 303 $$\mu m$$ μ m (SD: $$80\mu m)$$ 80 μ m ) at 1 month and 313 $$\mu m$$ μ m (SD: $$44\mu m)$$ 44 μ m ) at 12 months. Conclusions The DEX implant as monotherapy for macular edema in non-infectious uveitis was associated with a reduction in CRT and improvement in BCVA. The DEX implant, used as a monotherapy in eyes with intermediate, posterior and panuveitis, has the potential to treat uveitis without oral corticosteroid or other immunomodulatory therapy.https://doi.org/10.1186/s12348-023-00360-3DexamethasoneDexamethasone Intravitreal ImplantMacular EdemaNon-infectious Uveitis
spellingShingle Rishi B. Gupta
Julius Ilin
Chloe C. Gottlieb
Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
Journal of Ophthalmic Inflammation and Infection
Dexamethasone
Dexamethasone Intravitreal Implant
Macular Edema
Non-infectious Uveitis
title Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
title_full Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
title_fullStr Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
title_full_unstemmed Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
title_short Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis
title_sort efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non infectious uveitis a retrospective analysis
topic Dexamethasone
Dexamethasone Intravitreal Implant
Macular Edema
Non-infectious Uveitis
url https://doi.org/10.1186/s12348-023-00360-3
work_keys_str_mv AT rishibgupta efficacyofintravitrealdexamethasoneimplantusedasmonotherapyforthetreatmentofmacularedemainnoninfectiousuveitisaretrospectiveanalysis
AT juliusilin efficacyofintravitrealdexamethasoneimplantusedasmonotherapyforthetreatmentofmacularedemainnoninfectiousuveitisaretrospectiveanalysis
AT chloecgottlieb efficacyofintravitrealdexamethasoneimplantusedasmonotherapyforthetreatmentofmacularedemainnoninfectiousuveitisaretrospectiveanalysis